SGLT2阻害薬の心血管腎抑制効果はDM罹病期間でかわるか？

★

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE trials. Diabetes Care. 2024 Jan 22:dc231450. doi: 10.2337/dc23-1450. Epub ahead of print. PMID: 38252809.

Pubmed

24/1/22

Diabetes Care

介入試験

CANVAS、CREDENCE事後。
DM病歴 <5、5-10、10-15、≧15年で層別しても異質性なく、
罹病期間によらず効果は一定。